-+ 0.00%
-+ 0.00%
-+ 0.00%

Cerenome reports no dose-limiting toxicities in interim REYOBIQ repeat-dose study

PUBT·11/16/2026 12:32:25
Listen to the news
Cerenome reports no dose-limiting toxicities in interim REYOBIQ repeat-dose study
  • Cerenome presented interim ReSPECT-LM results supporting repeat REYOBIQ dosing for leptomeningeal metastases at the SNO meeting on November 13, 2026.
  • The first 10 patients experienced no dose-limiting toxicities or adverse events leading to treatment discontinuation.
  • No disease progression was documented among evaluable patients at early follow-up milestones, though progression occurred in one patient at a later assessment.
  • The preliminary findings do not establish a survival benefit; enrollment and dose escalation remain ongoing.
  • A randomized Phase 2 study is targeted for 2027, subject to clinical progress and regulatory alignment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160730PRIMZONEFULLFEED9878074) on November 16, 2026, and is solely responsible for the information contained therein.